The Asia Pacific Rapid Acting Insulin Market would witness market growth of 6.9% CAGR during the forecast period (2021-2027). The growth of the rapid-acting insulin market is expected to be fuelled due to various factors. An unhealthy and sedentary lifestyle is one of the prime factors which is creating profitable growth opportunities for the global rapid-acting insulin market during the forecast period. Along with this, other aspects like family diabetic history, unhealthy eating habits, and higher insulin resistance will augment the number of diabetes patients across the world. This would further support the demand and growth of rapid-acting insulin in the upcoming years.
Moreover, the global rapid-acting insulin market would be driven by the growing number of research and development (R&D) activities for human recombinant insulin. Leading players operating in the rapid-acting insulin market are introducing unique and advanced rapid-acting insulins with an aim to cater the growing market demand. As per The Australian Centre for Complex Integrated Surgical Solutions (ACCISS) 2016 report, pharmaceutical giants like Sanofi, Novo Nordisk, and Eli Lily are currently dominating the rapid-acting insulin market. This offers momentum and possibility for the development of the rapid-acting insulin market.
The China market dominated the Asia Pacific Online Providers Market by Country in 2020, and would continue to be a dominant market till 2027. The Japan market is experiencing a CAGR of 8.7% during (2021 - 2027). Additionally, The India market is poised to grow at a CAGR of 8.6% during (2021 - 2027).
The Insulin Lispro market dominated the Malaysia Rapid Acting Insulin Market by Product Type in 2020, thereby, achieving a market value of $63.3 Million by 2027. The Insulin Aspart market is expected to witness a CAGR of 8.7% during (2021 - 2027).
Based on Product Type, the market is segmented into Insulin Lispro, Insulin Aspart and Insulin Glulisine. Based on Indication, the market is segmented into Type 2 Diabetes and Type 1 Diabetes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Rapid Acting Insulin Market is Projected to reach USD 11.4 Billion by 2027, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Adocia SA, Biocon Limited, Gan & Lee Pharmaceuticals, Geropharm LLC, Wockhardt Ltd., and MannKind Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Product Type
- Insulin Lispro
- Insulin Aspart
- Insulin Glulisine
By Indication
- Type 2 Diabetes
- Type 1 Diabetes
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Providers
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Merck & Co., Inc.
- Sanofi S.A.
- Novo Nordisk A/S
- Eli Lilly and Company
- Adocia SA
- Biocon Limited
- Gan & Lee Pharmaceuticals
- Geropharm LLC
- Wockhardt Ltd.
- MannKind Corporation
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Rapid Acting Insulin Market, by Product Type
1.4.2 Asia Pacific Rapid Acting Insulin Market, by Indication
1.4.3 Asia Pacific Rapid Acting Insulin Market, by Distribution Channel
1.4.4 Asia Pacific Rapid Acting Insulin Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
Chapter 4. Asia Pacific Rapid Acting Insulin Market by Product Type
4.1 Asia Pacific Insulin Lispro Market by Country
4.2 Asia Pacific Insulin Aspart Market by Country
4.3 Asia Pacific Insulin Glulisine Market by Country
Chapter 5. Asia Pacific Rapid Acting Insulin Market by Indication
5.1 Asia Pacific Type 2 Diabetes Market by Country
5.2 Asia Pacific Type 1 Diabetes Market by Country
Chapter 6. Asia Pacific Rapid Acting Insulin Market by Distribution Channel
6.1 Asia Pacific Hospital Pharmacies Market by Country
6.2 Asia Pacific Drug Stores & Retail Pharmacies Market by Country
6.3 Asia Pacific Online Providers Market by Country
Chapter 7. Asia Pacific Rapid Acting Insulin Market by Country
7.1 China Rapid Acting Insulin Market
7.1.1 China Rapid Acting Insulin Market by Product Type
7.1.2 China Rapid Acting Insulin Market by Indication
7.1.3 China Rapid Acting Insulin Market by Distribution Channel
7.2 Japan Rapid Acting Insulin Market
7.2.1 Japan Rapid Acting Insulin Market by Product Type
7.2.2 Japan Rapid Acting Insulin Market by Indication
7.2.3 Japan Rapid Acting Insulin Market by Distribution Channel
7.3 India Rapid Acting Insulin Market
7.3.1 India Rapid Acting Insulin Market by Product Type
7.3.2 India Rapid Acting Insulin Market by Indication
7.3.3 India Rapid Acting Insulin Market by Distribution Channel
7.4 South Korea Rapid Acting Insulin Market
7.4.1 South Korea Rapid Acting Insulin Market by Product Type
7.4.2 South Korea Rapid Acting Insulin Market by Indication
7.4.3 South Korea Rapid Acting Insulin Market by Distribution Channel
7.5 Singapore Rapid Acting Insulin Market
7.5.1 Singapore Rapid Acting Insulin Market by Product Type
7.5.2 Singapore Rapid Acting Insulin Market by Indication
7.5.3 Singapore Rapid Acting Insulin Market by Distribution Channel
7.6 Malaysia Rapid Acting Insulin Market
7.6.1 Malaysia Rapid Acting Insulin Market by Product Type
7.6.2 Malaysia Rapid Acting Insulin Market by Indication
7.6.3 Malaysia Rapid Acting Insulin Market by Distribution Channel
7.7 Rest of Asia Pacific Rapid Acting Insulin Market
7.7.1 Rest of Asia Pacific Rapid Acting Insulin Market by Product Type
7.7.2 Rest of Asia Pacific Rapid Acting Insulin Market by Indication
7.7.3 Rest of Asia Pacific Rapid Acting Insulin Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Merck & Co., Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.2 Sanofi S.A.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Product Launches and Product Expansions:
8.2.5.2 Approvals and Trials:
8.3 Novo Nordisk A/S
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental & Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Product Launches and Product Expansions:
8.3.5.2 Approvals and Trials:
8.3.5.3 Partnerships, Collaborations, and Agreements:
8.4 Eli Lilly and Company
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.4.5.2 Approvals and Trials:
8.4.5.3 Partnerships, Collaborations, and Agreements:
8.5 Adocia SA
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expense
8.5.4 Recent strategies and developments:
8.5.4.1 Approvals and Trials:
8.6 Biocon Limited
8.6.1 Company Overview
8.6.2 Recent strategies and developments:
8.6.2.1 Approvals and Trials:
8.7 Gan & Lee Pharmaceuticals
8.7.1 Company Overview
8.7.2 Financial Analysis
8.8 Geropharm LLC
8.8.1 Company Overview
8.9 Wockhardt Ltd.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. MannKind Corporation
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expense
8.10.4 Recent strategies and developments:
8.10.4.1 Acquisition and Mergers:
8.10.4.2 Partnerships, Collaborations, and Agreements:
TABLE 1 Asia Pacific Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 2 Asia Pacific Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Rapid Acting Insulin Market]
TABLE 4 Product Launches And Product Expansions– Rapid Acting Insulin Market
TABLE 5 Acquisition and Mergers– Rapid Acting Insulin Market
TABLE 6 Approvals and Trials– Rapid Acting Insulin Market
TABLE 7 Asia Pacific Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 8 Asia Pacific Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 9 Asia Pacific Insulin Lispro Market by Country, 2017 - 2020, USD Million
TABLE 10 Asia Pacific Insulin Lispro Market by Country, 2021 - 2027, USD Million
TABLE 11 Asia Pacific Insulin Aspart Market by Country, 2017 - 2020, USD Million
TABLE 12 Asia Pacific Insulin Aspart Market by Country, 2021 - 2027, USD Million
TABLE 13 Asia Pacific Insulin Glulisine Market by Country, 2017 - 2020, USD Million
TABLE 14 Asia Pacific Insulin Glulisine Market by Country, 2021 - 2027, USD Million
TABLE 15 Asia Pacific Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 16 Asia Pacific Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 17 Asia Pacific Type 2 Diabetes Market by Country, 2017 - 2020, USD Million
TABLE 18 Asia Pacific Type 2 Diabetes Market by Country, 2021 - 2027, USD Million
TABLE 19 Asia Pacific Type 1 Diabetes Market by Country, 2017 - 2020, USD Million
TABLE 20 Asia Pacific Type 1 Diabetes Market by Country, 2021 - 2027, USD Million
TABLE 21 Asia Pacific Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 22 Asia Pacific Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 23 Asia Pacific Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 24 Asia Pacific Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 25 Asia Pacific Drug Stores & Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 26 Asia Pacific Drug Stores & Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 27 Asia Pacific Online Providers Market by Country, 2017 - 2020, USD Million
TABLE 28 Asia Pacific Online Providers Market by Country, 2021 - 2027, USD Million
TABLE 29 Asia Pacific Rapid Acting Insulin Market by Country, 2017 - 2020, USD Million
TABLE 30 Asia Pacific Rapid Acting Insulin Market by Country, 2021 - 2027, USD Million
TABLE 31 China Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 32 China Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 33 China Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 34 China Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 35 China Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 36 China Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 37 China Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 38 China Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 39 Japan Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 40 Japan Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 41 Japan Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 42 Japan Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 43 Japan Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 44 Japan Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 45 Japan Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 46 Japan Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 47 India Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 48 India Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 49 India Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 50 India Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 51 India Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 52 India Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 53 India Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 54 India Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 55 South Korea Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 56 South Korea Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 57 South Korea Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 58 South Korea Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 59 South Korea Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 60 South Korea Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 61 South Korea Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 62 South Korea Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 63 Singapore Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 64 Singapore Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 65 Singapore Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 66 Singapore Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 67 Singapore Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 68 Singapore Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 69 Singapore Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 70 Singapore Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 71 Malaysia Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 72 Malaysia Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 73 Malaysia Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 74 Malaysia Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 75 Malaysia Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 76 Malaysia Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 77 Malaysia Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 78 Malaysia Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 79 Rest of Asia Pacific Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 80 Rest of Asia Pacific Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 81 Rest of Asia Pacific Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 82 Rest of Asia Pacific Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 83 Rest of Asia Pacific Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 84 Rest of Asia Pacific Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 85 Rest of Asia Pacific Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 86 Rest of Asia Pacific Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 87 key information - Merck & Co., Inc.
TABLE 88 Key Information – Sanofi S.A.
TABLE 89 Key information – Novo Nordisk A/S
TABLE 90 Key Information – Eli Lilly and Company
TABLE 91 key information – Adocia SA
TABLE 92 Key Information – Biocon Limited
TABLE 93 Key Information – Gan & Lee Pharmaceuticals
TABLE 94 key Information – Geropharm LLC
TABLE 95 Key Information – Wockhardt Ltd.
TABLE 96 Key Information – MannKind Corporation
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2016-2020)
FIG 4 Recent strategies and developments: Novo Nordisk A/S
FIG 5 Recent strategies and developments: Eli Lilly and Company
FIG 6 Recent strategies and developments: MannKind Corporation